“If the $1 billion that Hevolution has committed to direct towards aging research will be spent on these dual-purpose aging- and disease-related targets, it will be more than the NIH spent on these targets in the context of aging in the past 30+ years! Even if it disperses the funds across the industry, it will result in a significant increase in total funding globally.” 

Inside Saudi Arabia’s $20 Billion Bet On Longevity Biotechnology [Forbes]